Precisely powerful

At Convergent Therapeutics, we’re fueled by our unwavering mission to unlock the full potential of alpha radioantibodies to help improve the lives of patients who are battling cancer.

Radiating promise

Radiation therapy has long been a powerful tool in oncology, including in prostate cancer.

By focusing on radioantibodies—specifically antibodies that deliver alpha-emitting payloads—we’re taking radiation therapy to the next level by making it more targeted and effective.

The powerful, short-range nature of our alpha payloads minimizes radiation exposure to healthy neighboring cells and tissues. When linked to our proprietary antibodies, the final result is a potent and precise radioantibody that is able to specifically target cancer cells and deliver the radioactive payload directly into the cell.¹